Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

Applicability of gene expression profile of childhood acute lymphoblastic leukemia at diagnosis and at the end of the induction phase of chemotherapy at a cancer hospital in the state of Goiás (Brazil)

verfasst von: Lysa B. Minasi, Fernanda R. Godoy, Daniela de M. e Silva, Thaís C. Vieira, Cláudio C. da Silva, Aparecido D. da Cruz

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The present study compared the gene expression pattern of some previously described genes at the time of diagnosis and after induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) in patients submitted to Brazilian Childhood Leukemia Treatment Group (GBTLI) ALL-99 Protocol. Samples were obtained at the time of diagnosis from 16 patients with ALL and on the 28th day of induction chemotherapy the bone marrow samples were obtained from 12 children. The genes expression profiles in diagnostic and induction samples were analyzed by array-based qPCR and then related to the clinical and biological prognostic factors. The results showed significant associations (p ≤ 0.05) between gender and immunophenotype, immunophenotype and age, immunophenotype and risk group, presence of CD10 and RUNX1 expression, risk group, and immunophenotype. A significant positive correlation was observed between the expression levels of BAX and BCL2. There was a significant difference (p = 0.008) between the gene expression pattern at the time of diagnosis and after induction chemotherapy. The expression pattern of these genes after the induction phase of treatment approached the expression profile of the control group, indicating a good induction response in children treated according to the GBTLI ALL-99 protocol. The findings of the current research could be routinely useful for clinical practice and could assist in the discovery phase of medical applications.
Literatur
1.
Zurück zum Zitat Hasani SS, Hashemi M, Eskandari-Nasab E, Naderi M, Omrani M, Sheybani-Nasab M. A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report. Tumor Biol. 2013. In press. Hasani SS, Hashemi M, Eskandari-Nasab E, Naderi M, Omrani M, Sheybani-Nasab M. A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report. Tumor Biol. 2013. In press.
2.
Zurück zum Zitat Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102(8):2951–9.PubMedCrossRef Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102(8):2951–9.PubMedCrossRef
3.
Zurück zum Zitat Pui C-H, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165–74.PubMedCrossRef Pui C-H, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165–74.PubMedCrossRef
5.
Zurück zum Zitat Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer cell. 2012;22(2):209–21.PubMedCentralPubMedCrossRef Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer cell. 2012;22(2):209–21.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Peter A, Heiden T, Taube T, Körner G, Seeger K. Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses–analysis of clinical relevance of additional TEL and AML1 copy number changes. Eur J Haematol. 2009;83(5):420–32.PubMedCrossRef Peter A, Heiden T, Taube T, Körner G, Seeger K. Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses–analysis of clinical relevance of additional TEL and AML1 copy number changes. Eur J Haematol. 2009;83(5):420–32.PubMedCrossRef
7.
Zurück zum Zitat Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol. 2012;2012(542308). Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol. 2012;2012(542308).
8.
Zurück zum Zitat Graux C. Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance. Transfus Apher Sci. 2011;44(2):183–9.PubMedCrossRef Graux C. Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance. Transfus Apher Sci. 2011;44(2):183–9.PubMedCrossRef
9.
Zurück zum Zitat Lanciotti M, D’Apolito M, Paolucci P, Indaco S, Dufour C. Gene expression profiling: a possible tool in the prediction of outcome in paediatric acute lymphoblastic leukaemia? Br J Haematol. 2011;153(2):279–82.PubMedCrossRef Lanciotti M, D’Apolito M, Paolucci P, Indaco S, Dufour C. Gene expression profiling: a possible tool in the prediction of outcome in paediatric acute lymphoblastic leukaemia? Br J Haematol. 2011;153(2):279–82.PubMedCrossRef
10.
Zurück zum Zitat Silveira VS, Scrideli CA, Moreno DA, Yunes JA, Queiroz RG, Toledo SC, et al. Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia. Leukemia Lymphoma. 2012;54(2):310–4.PubMedCrossRef Silveira VS, Scrideli CA, Moreno DA, Yunes JA, Queiroz RG, Toledo SC, et al. Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia. Leukemia Lymphoma. 2012;54(2):310–4.PubMedCrossRef
11.
Zurück zum Zitat Andersson A, Edén P, Olofsson T, Fioretos T. Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies. BMC Med genomics. 2010;3(1):6.PubMedCentralPubMedCrossRef Andersson A, Edén P, Olofsson T, Fioretos T. Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies. BMC Med genomics. 2010;3(1):6.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Kang H, Chen I-M, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood. 2010;115(7):1394–405.PubMedCrossRef Kang H, Chen I-M, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood. 2010;115(7):1394–405.PubMedCrossRef
13.
Zurück zum Zitat Brandalise SR, Pinheiro VR, Aguiar SS, Matsuda EI, Otubo R, Yunes JA, et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group—protocol ALL-99. J Clin Oncol. 2010;28(11):1911–8.PubMedCrossRef Brandalise SR, Pinheiro VR, Aguiar SS, Matsuda EI, Otubo R, Yunes JA, et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group—protocol ALL-99. J Clin Oncol. 2010;28(11):1911–8.PubMedCrossRef
14.
Zurück zum Zitat McCune B, Mefford, MJ. PC-ORD. Multivariate analysis of ecological data.Version 5.15.MjM software design, Gleneden Beach, Oregon, USA 2006. McCune B, Mefford, MJ. PC-ORD. Multivariate analysis of ecological data.Version 5.15.MjM software design, Gleneden Beach, Oregon, USA 2006.
15.
Zurück zum Zitat Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000;243(1–2):59–75.PubMedCrossRef Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000;243(1–2):59–75.PubMedCrossRef
16.
Zurück zum Zitat Supriyadi E, Veerman AJ. Detection of CD10, CD34 and their combined expression on childhood acute lymphoblastic leukemia and the association with clinical outcome in Indonesia. J cancer Ther Res. 2012;1(1):20.CrossRef Supriyadi E, Veerman AJ. Detection of CD10, CD34 and their combined expression on childhood acute lymphoblastic leukemia and the association with clinical outcome in Indonesia. J cancer Ther Res. 2012;1(1):20.CrossRef
17.
Zurück zum Zitat C-H PUI, Rivera G, Hancock M, Raimondi S, Sandlund J, Mahmoud H, et al. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. Leukemia. 1993;7(1):35–40. C-H PUI, Rivera G, Hancock M, Raimondi S, Sandlund J, Mahmoud H, et al. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. Leukemia. 1993;7(1):35–40.
18.
Zurück zum Zitat Consolini R, Legitimo A, Rondelli R, Guguelmi C, Barisone E, Lippi A, et al. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica. 1998;83(11):967–73.PubMed Consolini R, Legitimo A, Rondelli R, Guguelmi C, Barisone E, Lippi A, et al. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica. 1998;83(11):967–73.PubMed
19.
Zurück zum Zitat Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A. CD10 and CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome. Pediatr Hematol-Oncol. 2009;26(4):216–31.PubMedCrossRef Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A. CD10 and CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome. Pediatr Hematol-Oncol. 2009;26(4):216–31.PubMedCrossRef
20.
Zurück zum Zitat Taniuchi I, Osato M, Ito Y. Runx1: no longer just for leukemia. EMBO J. 2012;31(21):4098–9.PubMedCrossRef Taniuchi I, Osato M, Ito Y. Runx1: no longer just for leukemia. EMBO J. 2012;31(21):4098–9.PubMedCrossRef
21.
Zurück zum Zitat Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005;5(5):376–87.PubMedCrossRef Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005;5(5):376–87.PubMedCrossRef
22.
Zurück zum Zitat Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, et al. Minimal residual disease values discriminate between low and high relapse risk in children with b-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster (ALL-BFM) Trials. J Clin Oncol. 2008;26(18):3046–50.PubMedCrossRef Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, et al. Minimal residual disease values discriminate between low and high relapse risk in children with b-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster (ALL-BFM) Trials. J Clin Oncol. 2008;26(18):3046–50.PubMedCrossRef
23.
Zurück zum Zitat Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM, Knuutila S. AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. Haematologica. 2000;85:362–6.PubMed Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM, Knuutila S. AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. Haematologica. 2000;85:362–6.PubMed
24.
Zurück zum Zitat Montero-Ruiz O, Alcantara-Ortigoza MA, Betancourt M, Juarez-Velazquez R, Gonzalez-Marquez H, Perez-Vera P. Expression of RUNX1 isoforms and its target gene BLK in childhood acute lymphoblastic leukemia. Leuk Res. 2012;36:1105–11.PubMedCrossRef Montero-Ruiz O, Alcantara-Ortigoza MA, Betancourt M, Juarez-Velazquez R, Gonzalez-Marquez H, Perez-Vera P. Expression of RUNX1 isoforms and its target gene BLK in childhood acute lymphoblastic leukemia. Leuk Res. 2012;36:1105–11.PubMedCrossRef
25.
Zurück zum Zitat Mikhail F, Serry K, Hatem N, Mourad Z, Farawela H, El Kaffash D, et al. AML1 gene over-expression in childhood acute lymphoblastic leukemia. Leukemia. 2002;16(4):658–68.PubMedCrossRef Mikhail F, Serry K, Hatem N, Mourad Z, Farawela H, El Kaffash D, et al. AML1 gene over-expression in childhood acute lymphoblastic leukemia. Leukemia. 2002;16(4):658–68.PubMedCrossRef
26.
Zurück zum Zitat Harewood L, Robinson H, Harris R, Al-Obaidi MJ, Jalali G, Martineau M, et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia. 2003;17(3):547–53.PubMedCrossRef Harewood L, Robinson H, Harris R, Al-Obaidi MJ, Jalali G, Martineau M, et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia. 2003;17(3):547–53.PubMedCrossRef
27.
Zurück zum Zitat Planagumà J, Díaz-Fuertes M, Gil-Moreno A, Abal M, Monge M, García A, et al. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res. 2004;64(24):8846–53.PubMedCrossRef Planagumà J, Díaz-Fuertes M, Gil-Moreno A, Abal M, Monge M, García A, et al. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res. 2004;64(24):8846–53.PubMedCrossRef
29.
Zurück zum Zitat Tremblay M, Tremblay CS, Herblot S, Aplan PD, Hébert J, Perreault C, et al. Modeling T cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Gene Dev. 2010;24(11):1093–105.PubMedCrossRef Tremblay M, Tremblay CS, Herblot S, Aplan PD, Hébert J, Perreault C, et al. Modeling T cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Gene Dev. 2010;24(11):1093–105.PubMedCrossRef
30.
Zurück zum Zitat De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T cell acute lymphoblastic leukemia. haematologica. 2005;90(8):1116–27.PubMed De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T cell acute lymphoblastic leukemia. haematologica. 2005;90(8):1116–27.PubMed
31.
Zurück zum Zitat Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer cell. 2002;1(1):75–87.PubMedCrossRef Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer cell. 2002;1(1):75–87.PubMedCrossRef
32.
Zurück zum Zitat Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta. 2004;1644(2–3):83–94.PubMedCrossRef Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta. 2004;1644(2–3):83–94.PubMedCrossRef
33.
Zurück zum Zitat Aref S, Salama O, Al-Tonbary Y, Mansour A. Assessment of bcl-2 expression ass modulator of Fas mediated apoptosis in acute leukemia. Hematology. 2004;9(2):113–21.PubMedCrossRef Aref S, Salama O, Al-Tonbary Y, Mansour A. Assessment of bcl-2 expression ass modulator of Fas mediated apoptosis in acute leukemia. Hematology. 2004;9(2):113–21.PubMedCrossRef
34.
Zurück zum Zitat Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood. 1996;87(3):1140–6.PubMed Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood. 1996;87(3):1140–6.PubMed
35.
Zurück zum Zitat Del Principe MI, Del Poeta G, Maurillo L, Buccisano F, Venditti A, Tamburini A, et al. P–glycoprotein and BCL–2 levels predict outcome in adult acute lymphoblastic leukaemia. Br J Haematol. 2003;121(5):730–8.PubMedCrossRef Del Principe MI, Del Poeta G, Maurillo L, Buccisano F, Venditti A, Tamburini A, et al. P–glycoprotein and BCL–2 levels predict outcome in adult acute lymphoblastic leukaemia. Br J Haematol. 2003;121(5):730–8.PubMedCrossRef
36.
Zurück zum Zitat El-Mahallawy H, Shakankiry N, El-Guindy S, El-Maghraby S, Abd E, Latif S, et al. The expression of Bcl-2 and Bax proteins and their clinical relevance in ALL and CLL patients. J Egyp Nat Cancer Inst. 2001;13(1):35–42. El-Mahallawy H, Shakankiry N, El-Guindy S, El-Maghraby S, Abd E, Latif S, et al. The expression of Bcl-2 and Bax proteins and their clinical relevance in ALL and CLL patients. J Egyp Nat Cancer Inst. 2001;13(1):35–42.
37.
Zurück zum Zitat El-Mahallawy H, Shakankiry N, El-Guindy S, El-Maghraby S, Abd E, Latif S, et al. The expression of Bcl-2 and Bax proteins and their clinical relevance in ALL and CLL patients. J Egyp Nat Cancer Inst. 2001;13(1):35–42. El-Mahallawy H, Shakankiry N, El-Guindy S, El-Maghraby S, Abd E, Latif S, et al. The expression of Bcl-2 and Bax proteins and their clinical relevance in ALL and CLL patients. J Egyp Nat Cancer Inst. 2001;13(1):35–42.
38.
Zurück zum Zitat Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood. 1999;93(8):2671–8.PubMed Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood. 1999;93(8):2671–8.PubMed
39.
Zurück zum Zitat Gala J, Vermylen C, Cornu G, Ferrant A, Michaux J, Philippe M, et al. High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis. Ann Hematol. 1994;69(1):17–24.PubMedCrossRef Gala J, Vermylen C, Cornu G, Ferrant A, Michaux J, Philippe M, et al. High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis. Ann Hematol. 1994;69(1):17–24.PubMedCrossRef
40.
Zurück zum Zitat Kaparou M, Choumerianou D, Perdikogianni C, Martimianaki G, Kalmanti M, Stiakaki E. Enhanced levels of the apoptotic BAX/BCL-2 ratio in children with acute lymphoblastic leukemia and high-risk features. Genet Mol Biol. 2013;36(1):7–11.PubMedCrossRef Kaparou M, Choumerianou D, Perdikogianni C, Martimianaki G, Kalmanti M, Stiakaki E. Enhanced levels of the apoptotic BAX/BCL-2 ratio in children with acute lymphoblastic leukemia and high-risk features. Genet Mol Biol. 2013;36(1):7–11.PubMedCrossRef
41.
Zurück zum Zitat Ayres M, Ayres JR, Ayres DL, Santos AS. Bioestat5.0: Aplicações estatísticas nas áreas de ciências biológicas e médicas.Belém: Sociedade Civil Mamirauá. 2007. Ayres M, Ayres JR, Ayres DL, Santos AS. Bioestat5.0: Aplicações estatísticas nas áreas de ciências biológicas e médicas.Belém: Sociedade Civil Mamirauá. 2007.
Metadaten
Titel
Applicability of gene expression profile of childhood acute lymphoblastic leukemia at diagnosis and at the end of the induction phase of chemotherapy at a cancer hospital in the state of Goiás (Brazil)
verfasst von
Lysa B. Minasi
Fernanda R. Godoy
Daniela de M. e Silva
Thaís C. Vieira
Cláudio C. da Silva
Aparecido D. da Cruz
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1192-2

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.